Trusted Resource for Clinical Trials, Protocols & Progress
While blockchain is commonly associated with cryptocurrency, its potential extends far into regulated industries like pharmaceuticals. In clinical research, blockchain offers a secure, immutable, and decentralized infrastructure for managing sensitive data, audit trails, and compliance workflows.
Click to read the full article.
Data integrity is a cornerstone of Good Clinical Practice (GCP). Clinical trial records must be accurate, attributable, legible, contemporaneous, original, and complete—collectively known as ALCOA+. Any modification or tampering can lead to regulatory rejection or even legal consequences.
Click to read the full article.
While blockchain is often discussed in theoretical terms, real-world adoption in clinical trials is growing. Leading pharmaceutical companies and CROs are exploring how blockchain can solve challenges related to data transparency, audit trail integrity, and protocol compliance.
Click to read the full article.
Informed consent and audit trails are among the most inspected and error-prone areas in clinical trials. Missing timestamps, outdated ICF versions, or incomplete audit trails can result in serious regulatory findings. Traditional systems often rely on manual updates and siloed databases, which are difficult to audit consistently.
Click to read the full article.
Patient trust is the bedrock of successful clinical trial enrollment and retention. In today’s decentralized and hybrid trial landscape, subjects are more digitally connected—and more skeptical—than ever before. They want assurance that their personal data is secure, consent is respected, and the sponsor operates with transparency.
Click to read the full article.
In 2024, a leading sponsor initiated a blockchain pilot in a Phase III multi-site oncology study spanning 24 global sites across North America, Europe, and Asia. The goal was to assess the feasibility and regulatory acceptability of a blockchain-powered trial master file (TMF), eConsent tracking, and CRA monitoring logs.
Click to read the full article.
Conducting clinical trials across multiple countries presents enormous regulatory, technological, and operational challenges. Varying privacy laws (GDPR, HIPAA, LGPD), inconsistent data formats, and disparate electronic systems make interoperability and compliance difficult. In such environments, data delays, duplication, and protocol deviations are common.
Click to read the full article.
The clinical research industry is undergoing a digital transformation fueled by blockchain, AI, remote monitoring, and decentralized trials. In parallel, data protection laws are expanding globally—demanding that sponsors and CROs not only comply with existing frameworks like GDPR and HIPAA, but also anticipate how these laws will evolve by 2030.
Click to read the full article.
A Data Protection Impact Assessment (DPIA) is a mandatory tool under the General Data Protection Regulation (GDPR) when processing activities are likely to result in high risk to individuals’ rights and freedoms. For clinical trials, this includes the use of:
Click to read the full article.
Informed consent is not just a signature—it is an ongoing process of ensuring patients understand their role in a clinical trial, the use of their personal data, and their right to withdraw at any time. Regulatory frameworks such as GCP, GDPR, and HIPAA all emphasize different facets of subject rights, and sponsors/CROs must integrate these into their consent workflows.
Click to read the full article.
